PMEF
NMRA icon

Point72 Middle East FZE’s Neumora Therapeutics NMRA Stock Holding History

Point72 Middle East FZE’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-43,713
Closed -$617K – 1756
2023
Q3 		$617K Buy
+43,713
New +$546K 0.02% 740

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Middle East FZE's NMRA Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 43,713 shares — an estimated $617K sold.

Point72 Middle East FZE first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $617K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 43,713 Neumora Therapeutics shares in Q4 2023, an estimated $617K.
  • Point72 Middle East FZE first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Neumora Therapeutics position peaked at $617K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.